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SUMMARY 
In spite of major therapeutic advances, cancer relapse and low rates of patient 
response to cancer therapeutics persist. This failure is due in part to a small subpopulation 
of tumor initiating cells (TICs) with stem cell-like properties that are responsible for the 
growth of the tumor and the progression of metastasis. These cells are capable of 
surviving chemotherapy, rendering them highly resistant to conventional cancer 
therapies. Although the question of whether TICs are stem cells remains a controversial 
topic in the cancer field, it has become increasingly evident that a better understanding of 
their biology and function is necessary to effectively treat cancer and eradicate tumors 
without allowing for relapse to occur.  
This project aimed to develop an objective, label-free, fast, and scalable method 
for cancer cell and TIC enrichment based on the adhesion strength signature of these 
cells. Currently, no efficient and reliable methods to isolate TICs exist. Although many in 
the field rely on surface marker expression profiles, these are variable and subjective, 
which hinders the study of TIC biology. Our lab has developed a technology to isolate 
cells based on their unique adhesion binding strength to a matrix. The novel technology 
(micro-Stem cell High- Efficiency Adhesion based Recovery [μSHEAR]) consists of a 
microfluidic device that applies varying degrees of detachment shear forces to adherent 
cells. Using this device, human pluripotent stem cells and their progeny have been 
isolated with high reproducibility, yield (>97%), purity (95-99%), and survival (>95%) 
rates (Singh et al, Nature Methods 2013). The process is fast (<10 min), label free, and 
scalable. Our hypothesis was that subtypes of cancer cells will exhibit distinct ‘adhesive 
 xiv 
force signatures’ that can be exploited to selectively purify TICs with high efficiency 
using the μSHEAR technology. The significance of this work was the development of a 






CHAPTER 1. INTRODUCTION AND SPECIFIC AIMS 
1.1 Introduction 
Tumor initiating cells (TICs), a subpopulation of cancerous cells within tumors 
responsible for their maintenance, present a major hurdle to cancer treatment and 
recovery because of their resistance to conventional therapies [48-51]. While 
conventional cancer therapies target and often succeed in killing the bulk of the tumor’s 
cancer cells, TICs, sometimes called cancer stem cells (CSC) or cancer stem-like cells 
(CSLCs), are resistant to these treatments, surviving hostile microenvironments and 
driving cancer relapse and metastasis and relapse [52, 53]. Unlike bulk cancer cells, TICs 
have the ability to self-renew and differentiate into many subtypes of cancer cells. TICs 
have been identified in a variety of cancer types in both primary tumors and cancer cell 
lines by use of surface marker expression profiles as well as the ability to form 
tumorspheres and tumors [54]. Nevertheless, the surface marker expression profiles used 
to isolate TICs vary widely among cancer types and even within tumor samples and cell 
lines of the same cancer type (Table 2). The inability to isolate TICs with high 
purity/efficiency has complicated the development of novel therapies to specifically 
target these cells and continues to be a major hurdle in the cancer research and diagnostic 
fields. Our lab has recently developed a technology to isolate cells based on their unique 
adhesion binding strength to the matrix [30]. This novel technology (micro-Stem cell 
High- Efficiency Adhesion based Recovery [μSHEAR]) consists of a microfluidic device 
that applies varying degrees of shear force to adherent cells. Using this device, human 
pluripotent stem cells (both human induced pluripotent stem cells [hiPSCs] and human 
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embryonic stem cells [ESCs]) have been isolated from their parental cells, spontaneously 
differentiated cells, and partially reprogrammed cells with high reproducibility, yield 
(>97%), purity (95-99%), and survival (>95%) rates. The process is fast (<10 min), label 
free, and scalable. The objective of my project was to characterize the adhesion strength 
properties of cancer cells and TICs and exploit any differences to isolate them from each 
other and noncancerous somatic cells. I hypothesized that subtypes of cancer cells will 
exhibit distinct ‘adhesive force signatures’ that could be exploited to selectively purify 
TICs and cancer with using the μSHEAR technology. The objective of the project was 
achieved through the following specific aims. 
1.2  Specific Aim 1 
Examine the ability of the µSHEAR microfluidics platform to purify cancer cell 
populations from tumors. 
Tumors of mouse cancer cells (B16, E0771, 4T1) were explanted, dissociated, purified, 
and profiled using the microfluidic platform. The ability of the microfluidic platform to 
separate cancer cells from non- cancerous host cells was examined by use of time lapse 
microscopy with the E0771 cell line. This study established the ability of the integrated 
microfluidics platform to purify and identify cancer cell populations from tumors. 
1.3 Specific Aim 2 
Establish the ability of the µSHEAR platform to purify TIC sub-populations from 
cancer cell lines based on adhesive force signatures. 
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We studied the adhesion properties of a panel of human breast cancer cell lines, mouse 
cancer cell lines, and cells established from primary human colonic biopsies (CA2) by 
use of the hydrodynamic spinning disk technology and the μSHEAR technology. For the 
xenograft cell line CA2, the spinning disk technology was used to quantify differences in 
adhesion between cells expressing high levels of established TIC marker aldehyde 
dehydrogenase (ALDH) and those not expressing ALDH. For the mouse cell line E0771, 
isolated sub-populations were challenged using assays for tumor spheroid formation and 
invasiveness. Sub-populations of interest were then implanted into C57BL/6 mice to 
examine their ability to form tumors. This study demonstrated that TIC sub-populations 
could be purified by differences in adhesive force signature and the correlation between 
adhesive force signature and surface marker profile and tumorigenicity. 
1.4 Innovation and Significance  
TIC-enriched populations have been identified in established cell lines and patient 
samples using a variety of techniques including discrete surface markers 
(CD44hi/CD24lo, CD133+, ALDH+, ESA+) and their ability to generate tumorspheres 
and xenograft tumors. Although surface marker expression is the most widely used 
method for TIC isolation, the expression profiles vary widely among cancer of different 
tissue origin and, moreover, among TIC populations of different tumors and cell lines 
within a specific tissue. To date, there is no universal marker profile to identify TICs. The 
inability to effectively, scalably, and objectively purify TIC subpopulations is a 
significant impediment to characterizing the biology of these cells with precision as well 
as analyzing patient samples for effective diagnosis or prognosis. Therefore, there is a 
significant and unmet need for unbiased, efficient, label-free technologies for the 
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identification and purification of various cancer cell populations from heterogeneous 
cultures and tumors. 
The proposed project is innovative because it will use state of the art bioengineering 
technologies develop a novel method of TIC isolation from both cancer cells lines and 
tumors. Furthermore, this novel technology provides an objective and label-free 
alternative to current TIC isolation approaches which will be fast, easy to use, and 
scalable. The method developed will have potential applications in cancer research by 
facilitating the study of TICs as well as clinically in cancer diagnostics and prognostics.  
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CHAPTER 2. LITERATURE REVIEW 
 [Adapted from Cermeño, E. A., & García, A. J. (2016). Tumor-Initiating Cells: 
Emerging Biophysical Methods of Isolation. Current stem cell reports, 2(1), 21-32.][54] 
Increasing numbers of parallels are being drawn between cancer and stem cell 
research. Until recently, cancer progression was described using mainly the clonal 
evolution model [52, 55, 56] which postulates that cancers evolve by a repeating process 
of clonal expansion, mutation, and selection. As cancer progresses, different mutations 
accumulate in clones within the tumor and selective pressure leads to the survival of 
some clones and the extinction of others in a manner similar to Darwinian natural 
selection. Within this model, all cancer cells have the ability to rapidly divide and give 
rise to a new tumor [56]. A growing body of data supports an alternative view of cancer, 
dubbed the cancer stem cell (CSC) model. In contrast to the clonal evolution model, the 
CSC model proposes a hierarchical organization of cells in which a small population of 
tumor-initiating cells (TICs) are capable of self-renewal into more TICs and 
‘differentiation’ into bulk cancer cells. As the name suggests, TICs are defined by their 
unique ability to initiate new tumors, whereas other cancer cells cannot, but also display 
distinct marker expression profiles, chemotherapy/drug resistance, and biophysical 




Table 1. Characteristics of TICs 
Property Description Reference 
Tumor initiation TICs have the capacity to form tumors that resemble the 
tumor of origin in immunodeficient hosts 
[61-63] 
Drug/stress resistance An increased resistance to stresses including hypoxia, 
radiation, chemotherapy, treatment with other cancer drugs 
has been observed in TICs. This has been party attributed 
to an enhanced DNA damage response as well as more 




Surface markers expression levels are widely used as tools 
for TIC purification. The markers vary widely among 
cancer types.  
[61, 68-70] 
High ALDH activity ALDH activity is increased in TICs which results in 
protection from ROS damage and increased survival 
[71, 72] 
Sphere formation TICs have an increased ability to grow and form spheroids 




The expression of pluripotent genes such as Oct4 and 




Higher mitochondrial membrane potential, lower quantity 
of mtDNA, and lower intracellular concentration of ATP 
and ROS have been observed in TICs  
[77] 
Changed cell adhesion The expression of adhesion proteins such as integrins is 
dysregulated, resulting in a changed cell adhesion profile  
[78, 79] 
Decreased cell stiffness  Decreased cell stiffness and increased deformability have 




The  increased activity of the ABC transporter results in 
differential staining of TICs by Hoechst 33342, allowing 
for isolation by SP staining 
[81] 
TICs are thought to be responsible for the maintenance, progression, recurrence, 
and metastasis of cancer [82, 83]. Often, their higher propensity to be drug-resistant 
allows TICs to survive conventional therapies and leads to drug resistant cancer relapse 
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and metastasis development [84-86]. It is for this reason that targeting TICs in cancer 
therapy has attracted such excitement from the field [55, 87, 88]. However, TICs are 
usually rare populations within a tumor and their purification has proven challenging, 
even after in vitro culture. Efficient isolation and enrichment of TICs would facilitate 
their study and the development of drugs that selectively target them. 
It is important to distinguish between the cancer cell of origin (CCO) that initiates 
a tumor and the CSCs/TICs that sustain it, as they may not necessarily be related [89]. 
The CCO is the original cell that accumulates the first genetic mutations that lead to 
cancer. While the CCO is involved in the initiation of the primary tumor, CSCs/TICs are 
involved in the maintenance of this tumor and the initiation of secondary ones [90]. The 
terms CSC and TIC are often used interchangeably to denote cancer cells that can self-
renew to make more of themselves as well as ‘differentiate’ into bulk cancer cells [91]. 
As mentioned previously, these cells are often referred to as  cancer stem cells because of 
the similarities to somatic stem cells and tumor initiating cells because they are able to 
initiate tumors in immunocompromised mice [92]. 
2.1 Controversies and the evolving CSC model 
The field has been plagued by controversy surrounding the existence and the 
properties of TICs, with many still doubting the existence of these cells [60, 93]. This 
debate has been caused in part by the use of the term ‘cancer stem cells’, which suggests 
that they are derived from somatic stem cells. TICs can develop from normal somatic 
stem cells as well as progenitors and perhaps even terminally differentiated cells [57, 94-
96]. Furthermore, TICs are referred to as cancer stem cells because the definition of a 
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stem cell is a cell that can both self-renew and differentiate, both of which a TIC can do 
[93, 97].  
Other controversies stem from reports that the percentage of TICs within a tumor 
varies widely, sometimes accounting for a small fraction whereas other times the vast 
majority of cancer cells have the ability to reinitiate tumors [60, 98]. Several studies have 
suggested that the melanoma TIC frequency varies from around 2% to greater than 40% 
[52, 99, 100]. In addition to demonstrating the vast variability in TIC frequency, these 
studies challenge the idea that only a small population of cells within a tumor are TICs. 
Regardless, populations of cells with TIC properties have been identified in a variety of 
cancers including those of lung [101], ovarian [102], brain [61], breast [62], colon[103], 
and prostate [104] origins which have the signature TIC characteristics outlined above. 
Although useful, the original CSC model for cancer progression has evolved over 
the years. Current evidence suggests an intermediary progenitor state in between the TICs 
and the differentiated cancer cells. While TICs are quiescent and self-renewing, 
progenitors, sometimes called transit-amplifying cells, rapidly proliferate and have a 
limited self-renewal capability [59, 105]. Notably, the CSC model and the clonal 
evolution models are not mutually exclusive, but rather extremes in a spectrum into 
which most tumors fall. While there is a hierarchy of cancer cell phenotypes, there is also 
clonal selection within the TIC population, with different clones evolving in parallel and 
experiencing selection [59, 106]. Furthermore, it seems that differentiated cancer cells 
can dedifferentiate and go back to a TIC state, although how often this happens is not 
known [55, 106, 107]. A new report also suggest the existence of several TIC states in 






phenotype associated with TIC phenotype [108]; epithelial proliferative TICs that are 
positive for the TIC marker aldehyde dehydrogenase (ALDH); and a double positive TIC 
population that is even more tumorigenic [55, 109].
 
2.2 Relationship between EMT and TICs 
Epithelial-mesenchymal transition (EMT) is an important process during 
embryogenesis which allows polarized epithelial cells to transdifferentiate into migratory 
and invasive mesenchymal cells [110, 111]. This process is also activated during cancer 
progression and is believed to be crucial driver of metastasis, enabling cells to migrate 
away from the primary tumor to secondary sites [112, 113]. EMT has been correlated 
with the acquisition of TIC properties [114-116]. Activation of EMT leads to the 
expression of TIC markers, increased ability to grow in suspension, and higher 
tumorigenesis in vivo [115]. However, recent studies have challenged the perception that 
EMT is crucial for cancer progression and TIC phenotype: one study showed that only 
some TICs undergo EMT, while others retain their epithelial phenotype [109], while 
another study showed that EMT inhibition does not affect lung metastasis [117]. The 
exact relationship between EMT and TICs, whether EMT activation results in TIC 
phenotype or just promotes it, and whether all TICs undergo EMT remains to be 
elucidated. What has been shown is that drivers of EMT such as Slug, Snail, and the Wnt 
pathway are implicated in the acquisition of TIC characteristics [47, 118]. Conversely, 
forced expression of pluripotency genes such as Oct4 and Nanog in breast cancer cells 





 cancer cells have activated EMT markers and a fibroblast-like 
morphology [112]. It may be that EMT facilitates TIC phenotype acquisition but is not 
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necessary for it. A more in depth discussion of this relationship can be found elsewhere 
[47, 114]. 
2.3 Relationship between CTCs and TICs 
Circulating tumor cells (CTC) are a population of cancerous cells that have been 
shed into the vascular or lymphatic systems [119, 120]. A significant amount of research 
has been done on CTCs since they can be used as a tool for cancer prognostic and other 
clinical applications [120-122]. Although they have been reported to be more aggressive 
than other cancer cells [123, 124], it is important to note that not all CTCs are TICs, but 
rather a fraction of them are [119, 122, 125, 126]. The CTCs that do not have the 
plasticity characteristic of the TIC phenotype are not capable of forming secondary 
tumors [122], suggesting that a cell needs to have properties of both CTCs and TICs in 
order to successfully metastasize [119]. A significant number of systems for CTC 
detection and isolation have been developed as discussed elsewhere [119, 122]. However, 
many of them rely on specific CTC markers, such as EpCAM, which may not be 
expressed in all CTCs [55, 119]. Therefore, there is still a significant need for the 
development of robust platforms to purify TICs. 
2.4 Methods of TIC purification 
Many different methods of TIC purification have been developed to exploit 
unique attributes in these cells. Common methods of enrichment include surface marker-
based purification and isolation based on TIC intrinsic functional markers, such as ALDH 
expression, reactive oxygen species (ROS) levels, flow cytometric side population (SP) 
analysis, and mitochondrial membrane potential differences. Many of these purification 
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platforms rely on probes such as antibodies and separation technologies such as flow 
cytometry and magnetic beads. Although popular, these methods have several drawbacks 
including high price, non-specificity, inability to scale-up, and lack of robustness, which 
have led to the recent development of biophysical methods of TIC purification based on 
differences in adhesion, stiffness, and niche/scaffold affinity. The methods of TIC 
enrichment are summarized on Figure 1. 
 
Figure 1 Methods of TIC purification, isolation, and enrichment. (a) Differential 
adhesion: Cells can be separated from surfaces based on their adhesion strength by 
applying defined amounts of force. (b) Differential stiffness: Cells are flowed through a 
microfluidic channel with diagonal ridges that interact with flowing cells. More 
deformable cells travel perpendicular to the ridges while stiffer cells attempt to travel 
parallel to them. (c) Niche mimicking/biomaterials: Cells are introduced into a 
biomaterial or plated on a coated surface that mimics some property of the TIC niche 
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which leads to enrichment of TICs and/or apoptosis of non-TICs. (d) Suspension culture: 
Cells are grown in suspension culture. TICs have an enhanced ability to grow in these 
conditions resulting in their enrichment. (e) Drug resistance: Culture is treated with a 
drug, which results in the apoptosis of non-TIC cancer cells. (f) Reporter-based selection: 
A reporter line is made with a fluorescent protein under the control of a TIC marker (e.g. 
pOct4-GFP). (g) In vivo tumorigenesis: Cells are introduced into an 
immunocompromised mouse. Only TICs have the ability to form tumors at low doses. 
2.5 Marker-based purification 
2.5.1 Surface markers 
Table 2. Common TIC surface markers 















































































































TICs have been identified in many types of solid tumors based on their expression 
of surface markers (Table 2). Various surface markers continue to be identified; however, 
no universal marker exists. Instead, TIC surface markers appear to be tissue specific and 
may vary among different tumors requiring extensive validation. Moreover, even well 
validated markers such as CD133 seem to fail to specifically identify TICs in certain 
applications [149, 150]. In spite of their limitations, surface markers are widely used for 
TIC purification, with some groups developing non-antibody based aptamer probes [151, 
152]. Many of the developed markers are conjugated with fluorescent  labels and used in 
combination with techniques such as fluorescence-activated cell sorting (FACS) [153] 
and magnetic-activated cell sorting (MACS) [86] for isolation. 
2.5.2 Intrinsic functional markers - ALDH 
ALDHs are a family of enzymes that play a role in the metabolism of aldehydes 
[154]. Studies dating more than a decade have described a correlation between high 
levels of ALDH and stemness and succeeded in isolating hematopoietic stem cells based 
on ALDH activity [155-157]. More recently, high ALDH levels have been associated 
with other stem cell types and with TICs [71, 72, 158-160]. Importantly, overexpression 
of some members of the ALDH family has been shown to be predictive of poor clinical 
outcome [161, 162]. This might be in part due to the role ALDH plays in drug resistance 
development, as these enzymes have been shown to help protect cells from reactive 
oxygen species (ROS) damage [163]. It seems that ALDH overexpression is a 
characteristic that TICs from different tissues share [159], making ALDH detection kits 
extremely useful for TIC isolation. Nevertheless, ALDH-based isolation is not capable of 
detecting all TICs, as even ALDH
low
 fractions of cancer cells can lead to the formation of 
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tumors in vivo [164]. In fact, recent studies suggest that tumors may have a subpopulation 
of TICs that are not characterized by the ALDH
high
 phenotype [109].  
Nevertheless, screening for cells expressing high levels of ALDH remains  a 
powerful tool for research into TIC biology and behavior. Xenograft lines with high 
percentages of ALDH
Hi
 cells have been developed and used to study the initiation and 
maintenance of cancer [165-168]. Their ability to maintain a large population of cells in a 
TIC-like state facilitates the research into the role TICs play in cancer progression. In 
particular, these lines have been a powerful tool for elucidating the role of TICs in the 
transition from colitis to colon cancer [165, 166] as well as the interactions of TICs with 
other important cell types in colon cancer[167, 168].  
2.5.3 Other functional markers 
Other functional markers for TICs include ROS levels [169], SP analysis by 
Hoechst 33342 staining [170], and differences in mitochondrial membrane potential [77]. 
Of these three methods, the SP exclusion is the most widely used. Although easy and 
simple to perform, SP exclusion can be culture condition-dependent, since the staining 
conditions influence the number positive cells and have low specificity [171].  
2.6 Biophysical methods of purification 
2.6.1 Adhesion-based purification 
The interaction between cells and their extracellular environment is of critical 
importance to normal development and function [172, 173]. Integrin receptors mediate 
this interaction by mechanically coupling to an extracellular matrix (ECM) ligand, 
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associating with the actin cytoskeleton and clustering together [174]. These interactions 
may strengthen to give rise to focal adhesions, which function as structural links between 
the cell’s cytoskeleton and the surrounding ECM [175]. Abnormal integrin function can 
lead to a variety of diseases, including cancer [176]. Other proteins involved in cell 
adhesion and focal adhesion complex formation such as focal adhesion kinase (FAK) 
[177, 178] are also dysregulated in cancer cells and, along with integrins, contribute to 
disease progression and metastasis. Integrins in particular are often upregulated in many 
types of cancer and the levels of several integrin subtypes are prognostic of disease 
severity [176]. In addition to having important roles in cancer cell survival, migration, 
and invasion, integrins have been shown to cooperate with oncogenes to increase 
tumorigenesis [176].  
Given that integrins and other important cell adhesion proteins are upregulated in 
cancer, it follows that cancer cells might bind to the ECM with a different amount of 
force than normal cells. A study by Kwon et al supports this premise, as they were able to 
separate breast cancer cells from normal mammary cells based on adhesion forces. MCF7 
breast cancer cells and MCF10A human breast epithelial cells were introduced into 
microfluidic channels, allowed to attach to gelatin-coated surface, and differentially 
detached using shear fluid forces [179]. A limitation of this study, however, is that only 
cell lines are used which might not recapitulate the behavior of primary cancer cells. 
 Cell adhesion proteins are also important for normal development and 
embryogenesis [180]. Integrins are essential for stem cell homing to their niche during 
embryogenesis and development [181]. Several studies have shown the feasibility of 
separating stem cells based on their adhesion levels and integrin expression profiles [30, 
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182, 183]. For example, our group recently demonstrated different levels of integrin 
expression in pluripotent stem cells (PSCs) and their differentiated progeny [30].  These 
differences resulted in differential ECM adhesion strengths that could be exploited to 
isolate PSCs from a mixture of differentiated and partially reprogrammed cells. 
Furthermore, these results suggest that upon differentiation, integrin expression levels 
change resulting in varying adhesion strengths to ECM proteins. 
 Given the vital role that adhesion proteins play in normal stem cell function, it is 
expected that they also play important roles in TICs. In fact, many adhesion proteins have 
been shown to promote TIC stemness. FAK ablation results in a depletion of the TIC 
population [184], integrin αvβ3 regulates expression of TIC marker CD44 [185] and is 
necessary to drive stemness and EGFR inhibitor resistance for epithelial cancers [186], 
and integrin α6β1 knockdown results in loss of stemness in TICs [187, 188]. In addition 
to simply being overexpressed in TICs, adhesion proteins potentiate TIC function and 
enable tumor propagation and drug resistance [189].  
 Abnormal expression and function of the cell-ECM adhesion apparatus in TICs 
have allowed groups to isolate them based on their adhesion dynamics. Bansal et al 
isolated prostate TICs from other cancer cells by allowing them to bind to collagen-
coated surfaces for a short period of time. They found that TICs bound faster, and by 
washing away other cells, cancer cells with stem-like properties could be enriched [78]. 
Zhang et al applied the same idea in a more controlled manner to isolate breast cancer 
TICs. They used a microfluidic platform to slowly flow cells through a channel coated 
with selected ECM proteins. Since the TICs interact more rapidly with the ECM, they 
became trapped in the channel, while other cells flowed through [79]. 
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It is important to note that adhesion strength separation can be done by exploiting 
differences in the rates at which cells bind to the substrate or differences in the amount of 
force required to detach adherent cells. When exploiting differences in binding rate, the 
cells are slowly rolled over a coated surface and some will bind faster that others 
allowing for separation. On the other hand, when exploiting differences in detachment 
force, cells are allowed to reach some level of adhesion strength with the ECM and then 
forces are applied to separate them. Although this might not seem like a major difference, 
the two assays measure different cell properties which may vary independently: the first 
how fast cells can form adhesion complexes and the second how strongly these adhesion 
complexes bind to the ECM. Thus far, only differences in binding speed have been 
exploited to isolate TICs. Separation based on detachment force might prove more useful 
since it is generally more scalable and robust.  
2.6.2 Stiffness-based purification 
Cell elasticity (i.e. stiffness) is another important mechanical property of cells, 
and it is modulated by the cytoskeleton which is comprised of actin filaments, 
microtubules, and intermediate filaments [190]. Cells are capable of regulating their 
elasticity by regulating the composition and organization of their cytoskeleton in 
response to internal and external cues [190, 191]. 
 Cell elasticity has been shown to be increased in cancer cells from a variety of 
tissues including those from breast, pancreatic, and ovarian origin [190, 192, 193]. Other 
studies have shown that the trend of decreased stiffness for cancer cells might not hold 
for cells from different tissues. In contrast to other cancer cells, brain cancer cells appear 
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to be less mechanically compliant than  non-cancerous cells [194]. In spite of this, the 
differences in cell stiffness between cancer cells and benign cells present the opportunity 
for stiffness-based separation of cancer cells. Several microfluidic platforms have been 
developed for this application. The platforms use diagonal ridges [195] or triangular posts 
[196] to force cells to deform as the flow through the channel. The cells deform to 
varying degrees depending on their elastic properties and travel differentially through the 
channels to different outlets. 
 Cell elasticity has been correlated to the metastatic potential of cells, with cells 
that are more elastic having higher invasive and migratory behaviors [193, 197-199]. It is 
speculated that the lower stiffness allows cells to squeeze through and migrate to other 
parts of the body. The activation of the EMT program in tumor cells would also make 
them more elastic, since the loss of adhesion and stiffness are hallmarks of EMT [200]. 
Interestingly, both the activation of the EMT program as well as metastatic potential 
correlate closely with TIC phenotype [201], suggesting some of the highly metastatic 
elastic cells studied above might have been TICs. Babahosseini et al used atomic force 
microscopy (AFM) to directly show that an enriched TIC population is at least 45% 
softer than other cancer cells [80]. Isolation of TICs should thus become feasible by using 
one of the stiffness fractioning microfluidic platforms mentioned earlier. One study 
suggests the feasibility of this approach. Highly elastic breast cancer cells were isolated 




 TIC phenotype. They were also 
tested for mammosphere formation, an ability unique to TICs [202]. Although 
encouraging, the study has severe limitation, since it does not include any primary tissue 
nor does it test the cells for tumor formation capacity in vivo. 
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2.6.3 Niche/biomaterial interaction based purification 
Similar to somatic stem cells, TICs have a niche which regulates their 
differentiation and self-renewal and protects them from the host’s immune system [203-
205]. Under certain conditions, TICs will home to normal stem cell niches and hijack 
them [206, 207]. A variety of methods for TIC enrichment have been developed which 
take advantage of their preferential adhesion or homing into specific scaffolds or 
topographies. A study by Tan et al demonstrated that breast TICs preferentially bind to a 
specific nanotopography, characterized by thinner grating. A significant enrichment was 






 phenotype when MCF7 cells were cultured in a 
nanopatterned surface with thin gratings as opposed to unpatterned surfaces and other 





population. It is difficult to determine which TIC phenotype was 
enriched for, since no functional testing was done on the cells and only low levels of ESA 
expression are associated with TICs, whereas ESA
hi
 is seen in luminal breast cancer cells 
[209]. More testing is therefore needed to assess the efficacy of nanopatterned surfaces 
for TIC enrichment.  
Another strategy involves culture within three-dimensional scaffolds to enrich for 
TIC populations. Different scaffolds have been used in this context including chitosan-
alginate scaffolds for glioblastoma [210] and hepatocellular carcinoma [211] TIC 
enrichment and collagen scaffolds for breast [212] and liver [213] TIC enrichment. In 
these examples, cancer cells infiltrate the scaffold and are maintained within them. The 
scaffold modulates cancer cell behaviors, resulting in an enrichment of cells with TIC 
markers, more resistance to chemotherapy/cancer drugs, and higher tumorigenesis in 
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vivo. Since this approach results in both enrichment of TICs and mimicking of in vivo 
environment of cancer cells, it might prove to be a useful tool for modeling in vivo 
behavior and screening new therapies. 
Other groups have gone a step further and attempted to model the TIC niche in 
order to isolate this population of cancer cells [213, 214]. Polyelectrolyte multilayers 
(PEM) nanofilms were used to fabricate microenvironments that simulated hepatocellular 
carcinoma TIC niches. Cells were then seeded on top of the PEM layer. After being 
cultured for 7 days, 70% of the cells were positive for CD44/CD133 TIC markers. This 
enrichment was due to cell death of non-TICs, presumably because the PEM/hyaluronic 
acid based environment mimics a TIC-niche topographical cue which is not conductive 
for their survival, and resulted in a population that was more resistant to chemotherapy 
agents. Further in vivo testing of the enriched populations is critical to validate this 
enrichment strategy. 
An exciting development is a platform for in vivo capture of early metastatic cells 
or CTCs [215].  Poly(lactide-co-glycolide) scaffolds were implanted in immunodeficient 
NSG mice that had undergone tumor inoculation 7 days beforehand with a highly 
metastatic variant of the MDA-MB-231 breast cancer cell lines. Cells not only homed to 
the scaffold, but the tumor burden on common metastatic sites was decreased five-fold, 
suggesting that cancer cells and TICs were being trapped in the scaffold and prevented 
from migrating elsewhere in the mouse. A light scattering technique could then be used 
to detect the cells in the scaffold in a label-free manner. Although this approach does not 
directly recruit TICs, one could envision modifying the scaffold to facilitate the homing 
of TICs. Therapeutically, this strategy could serve to deplete the remaining TIC 
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population after initial treatment and reduce the probability of cancer metastasis and 
relapse. 
All these approaches appear to enrich the TIC population by providing 
topological or adhesive cues that either decrease the survival of non-TICs or increase 
amount of cells that remain in the TIC state. The label-free, reproducibility, and relative 
ease of use are major advantages of these systems. Furthermore, most of them mimic 
elements of the in vivo environment of cancer cells, which can be useful for other 
applications such as disease modeling. Nevertheless, a major disadvantage might be the 
broad applicability of these platforms to different types of cancer. If they indeed work by 
mimicking the TIC niche, those niches might vary among cancers of different tissues. 
In summary, biophysical methods for TIC isolation and enrichment offer several 
advantages over marker based approaches. The label-free nature of biophysical methods 
leads to more objectivity as there is no bias towards a marker, less manipulation of the 
cells, and potentially lower costs. Furthermore, some of these methods are more easily 
scalable since they can be performed in large groups of cells instead of requiring each 
cell to be passed through a flow cytometer one at a time. Nevertheless, the biophysical 
properties of cells, including adhesion and stiffness, change when EMT is activated. If 
there indeed are both epithelial and mesenchymal TIC states [55, 109], then these 
approaches might not be able to isolate them both at the same time.  
2.7 Other methods of purification 
2.7.1 Suspension culture 
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It has become increasingly common to use suspension culture to isolate TICs. The 
spheres that form in these conditions express many of the TIC surface markers, have 
higher ALDH expression, and are drug resistant [73, 74, 216]. Although widely used, this 
system has several drawbacks. First, whereas the spheres do have some true TICs, many 
of the cells are differentiated progeny or progenitor cells, which are also able to form 
spheres, and contain a necrotic core [217-219]. There is also a large variation in the 
percentage of TICs within a sphere, partly caused by the variation in methodology that is 
employed, which may cause conflicting results and make cross comparison difficult 
among labs [218, 220, 221]. Some groups have attempted to encapsulate the spheres in a 
liquid core hydrogel, but the TIC enrichment remains fairly low at 25-30% [222]. Finally, 
suspension culture might not be able to detect quiescent TICs [220]. Some groups have 
even reported better results at isolating pure TIC cell lines by using adherent culture with 
defined media [219]. While useful in some situations, suspension culture has major 
drawbacks and attention should be paid to the methodology that is used. 
2.7.2 Drug selection 
In cancers that do not go into remission or which relapse after what appears to 
have been successful treatment, TICs have been shown to be chemoresistant [47, 223-
225] as well as resistant to other cancer drugs [65, 226] and even radiotherapy [66]. 
Moreover, treatment with drugs such as tamoxifen [65], temozolomide [227], and 
gemcitabine [228], trastuzumab [229], and staurosporine [230] results in the enrichment 
of cancer cells with TIC properties [64]. A growing body of literature suggests that this 
drug resistance allows TICs to survive conventional cancer treatments and leads to 
relapse and metastasis [47, 224]. The exact mechanism of drug resistance is not known, 
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but it probably involves a combination of ABC transporter expression, increased ALDH 
activity, enhanced DNA damage response, quiescence, and activation of other key 
signaling pathways [225]. The EMT process has also been associated with drug 
resistance acquisition [47, 231]. Several groups have taken advantage of this property to 
enrich TIC populations by treating the whole population of cells with chemotherapy or 
other cancer drugs [232-234]. This leads to the death of normal cancer cells and 
enrichment of the TIC population. However, there have been reports of cancer drug 
treatments changing the gene expression profiles of cancer cells [229, 230]. The changes 
in expression profiles could be due to changes in the relative amounts of TICs to non-
TICs as enrichment proceeds, but it could also be due to the process altering the cells 
themselves. If the cells are changing their gene expression in response to drug selection, 
this would present a major limitation since it would mean this method could not be used 
to isolate naïve TICs that have not been altered by drug selection. 
2.7.3 Reporter genes 
Pluripotency genes such as Oct4 and Nanog are expressed in TICs [75, 76]. This 
has led to the development of TIC reporter systems in which cancer cells expressing Oct4 
[235] or Nanog [236] express fluorescent proteins such as GFP. Interestingly, some of the 
procedures for reporter line derivation have caused the cells to get stuck in a TIC-like 
state in which the cells express TIC surface markers, have higher tumorigenesis and 
cancer drug resistance, and cannot exit the TIC state [235]. Although these reporter lines 
are useful in vitro systems, developing these lines is time intensive and genetically 
modifies the cells, which may impact other cells functions and behaviors. Furthermore, 
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this technique is not applicable when attempting to purify or enrich cells from primary 
human tumors. 
2.7.4 In vivo tumorigenesis 
By definition, TICs are characterized by their ability to form de novo tumors that 
resemble the primary tumor following transplantation [58, 61, 62]. A gold standard for 
the characterization and identification of TIC populations is their ability to form tumors 
in serial immunodeficient hosts. In contrast to TICs, differentiated cancer cells cannot 
give rise to a tumor and progenitor cells are not able to form tumors in serial hosts. 
Although it has not been shown that a single TIC can give rise to an entire tumor, 
significantly lower numbers of TICs are required to do so relative to bulk cancer cells. 
This limitation, however, might result from our technical inability to get completely pure 
populations of TICs and not a functional inability of single TICs to give rise to tumors. 
Although a gold standard, protocols and animal models for in vivo tumorigenic 
evaluation of TICs vary in the literature and a consensus has not yet been reached [60]. 
Moreover, by using mouse cancer lines derived from specific mouse strains, such 
as the E0771 mouse breast cancer cell line derived from the C57BL/6 mouse line, the 
ability of TICs to form tumors can be examined in immunocompetent mice. Similar 
tumor formation models have been developed in the cancer field [237-241]  and utilized 
to study a variety of cancer related fields including cancer drug development [238, 240], 
the role of metalloproteases in cancer progression [239], and processes involved in the 
progression of metastasis [241]. 
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2.8 Future directions 
TICs are a unique population of cells within tumors capable of establishing new 
tumors which drive cancer relapse and metastasis. While usually rare, TICs are resistant 
to chemotherapy and hypoxic environment. In vitro, they are detected by their expression 
of defined surface markers, ALDH activity, growth in suspension culture, drug 
resistance, and tumorigenesis in immunocompromised mice. Efficiently isolating TICs 
will be will be essential in order to diffuse the debate surrounding the existence and 
importance of TICs as well as to better understand their biology and develop new drugs 
that selectively target them.  
 Much effort has gone into identifying appropriate surface markers for TICs, 
which vary widely according to tissue of origin. It is important that other methods, such 
as the ones described here, are studied as well in order to develop more reproducible and 
robust methods for TIC purification.  
In summary, the development of the CSC model has revolutionized the cancer 
research field. Although the model continues to evolve, an impressive amount of data 
supports the existence of TICs in many cancers. Isolating them will be of pivotal 
importance to effectively treat and eradicate cancer. 
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CHAPTER 3. µSHEAR MEDIATED PURIFICATION OF 
CANCER CELL POPULATIONS FROM TUMORS 
3.1 Abstract 
It is estimated that 1,735,350 new cancer cases and 609,640 cancer deaths will occur in 
the US alone in 2018. Conventional treatment of cancer relies on standardized and 
predetermined therapeutic protocols determined by tumor histological analysis and organ 
of origin, which often center on systemic administration of cytotoxic chemotherapy. Over 
the last decades, deeper understanding of the molecular pathways that lead to cancer 
progression have allowed researchers to develop more targeted cancer therapies that take 
aim at the specific aberrations that have driven each particular cancer subtype. The 
targeted nature of these new therapies makes it necessary to identify which patient 
populations carry the genetic abnormalities targeted by each drug and what the optimal 
biomarkers are for the identification of said populations. We developed a method for 
isolating cancer cells based on their unique adhesion binding strength to extracellular 
matrix (ECM) proteins by using a adhesion based sorting technology micro-Stem cell 
High- Efficiency Adhesion based Recovery [μSHEAR]) consisting of a microfluidic 
device that applies varying degrees of shear force to adherent cells. This novel 
purification method is able to increase the frequency of cancer cells to ~60%, achieving a 




3.2 Introduction  
Cancer continues to be a major public health problem both worldwide and in the 
United States, where it is one of the leading causes of death, second only to heart disease, 
and accounted for 22% of total deaths in 2015 [1]. It is estimated that 1,735,350 new 
cancer cases and 609,640 cancer deaths will occur in the US alone in 2018 [1]. Although 
cancer incidence and death rates have both declined over the last decade (2005-2014), by 
9% and 15% respectively [1], the overall 5-year survival still remains low at around 61-
68% [2]. However, this decrease in cancer mortality has stemmed primarily from lifestyle 
changes and earlier detection and treatment of cancer cases, not necessarily from more 
advanced or efficient therapies [1, 3, 4]. Moreover, although overall cancer mortality 
rates have declined by about 1.5% per year since 1990, mortality rates have increased for 
some specific cancer types, including liver and pancreatic cancers [1]. 
Conventional treatment of cancer relies on standardized and predetermined 
therapeutic protocols determined by tumor histological analysis and organ of origin, 
which often center on systemic administration of cytotoxic chemotherapy [5, 6]. 
Although successful, these treatments have a high variability in response and success rate 
[7] and sometimes lead to severe side effects [6]. Over the last decades, deeper 
understanding of the molecular pathways that lead to cancer progression have allowed 
researchers to develop more targeted cancer therapies that take aim at the specific 
aberrations that have driven each particular cancer subtype [6, 8]. In fact, a new study 
performed an in depth analysis of the PanCancer Atlas, clustering tumors based on 
molecular alterations and not site of origin with the hope that the traditional method of 
organ of origin tumor classification can be supplemented with this novel clustering and 
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that this may lead to improved clinical trials and patient treatment responses [9]. This 
shift to a more personalized approach to cancer treatment is evident in the drugs approved 
by the FDA since 2000, with 15 being targeted therapies and only 5 being traditional 
chemotherapy agents [6]. Furthermore, cancer immunotherapies, specifically checkpoint 
inhibitors for solid tumors and adoptive T-cell therapy with chimeric antigen receptor T 
cells against B-cell–derived leukemia and lymphomas, are disrupting the therapeutic 
options available to patients. The excitement in the field is evident given that there are 
currently 200+ and 300+ clinical trials with 6 and 2 FDA approved drugs respectively for 
these two cancer therapy approaches. In essence, these immunotherapies rely on 
leveraging immune pathways, either through antibodies or genetically modified T cells, 
to inhibit the growth of established tumors and recruit the patient’s own immune system 
to attack and eradicate them [10, 11].  
Unlike conventional therapies, the targeted and personalized nature of these new 
therapies means that they will work optimally only on the cancer subtypes that have the 
genetic abnormalities that they target, while not necessarily providing a benefit in other 
cancer subtypes [12, 13]. This differential response makes it necessary to identify which 
patient populations carry the genetic abnormalities targeted by each drug and what the 
optimal biomarkers are for the identification of said populations [6, 8, 14, 15]. 
Another hurdle in the cancer field is the high propensity of failure of drug 
candidates undergoing clinical trials [16, 17]. Approximately 62% of clinical trials 
involving cancer drugs from 2005 to 2009 did not achieve statistical significance [18]. 
Furthermore, the estimated approval success rate for cancer drugs between 1993 and 
2004 was 13.4% [19]. This high failure rate might be due in part to the limited 
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availability of preclinical models in which to study prospective drugs, which often rely 
heavily on cancer cell lines [17]. Cancer cell lines accumulate a large amount of 
aberrations during their prolonged in vitro expansion [20, 21], which cause them to not be 
representative of clinical scenarios. Furthermore, the limited number of cell lines also 
fails to recapitulate the diversity of genetic and non-genetic aberrations present the large 
number of patients suffering from cancer [17, 22, 23]. 
Because of the need for better validation tools for preclinical testing and the need to 
identify novel biomarkers of the different cancer subtypes, novel methods for generating 
and culturing primary tumor cells from patients are important [17, 24-26]. Nevertheless, 
it is nontrivial to develop said lines successfully and the contamination of non-tumor cells 
in the cultures as well as normal stromal cells outcompeting cancer cells in long term 
culture remain hurdles that need to be overcome [27-29].  
Here, we characterized the adhesion properties of cancerous and noncancerous cells 
by use of the hydrodynamic spinning disk technology. Furthermore, we developed a 
method for isolating cancer cells based on their unique adhesion binding strength to the 
matrix by using a adhesion-based sorting technology micro-Stem cell High- Efficiency 
Adhesion based Recovery [μSHEAR]) [30] consisting of a microfluidic device that 
applies varying degrees of shear force to adherent cells. 
3.3 Materials and methods 
3.3.1 Cell culture 
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All human breast cancer cell lines as well as the hTERT-HME1 cell line were acquired 
from ATCC and cultured according to their protocols. E0771 cells were cultured in RPMI 
1640 supplemented with 10%FBS and 1% penicillin, and 1% Streptomycin at 37 ºC, 5% 
CO2. All cell lines were sub-cu ltured at 70-80% confluency. 
3.3.2 Spinning disk Assay 
Circular cover slips (25 mm diameter) were sterilized with ethanol, coated with 
fibronectin (10 μg/mL) for 30 min, and blocked with a 1% solution of bovine serum 
albumin (BSA) for 30min. Cells were seeded onto fibronectin-coated circular coverslips 
and cultured overnight at concentrations of 50,000-200,000 cells/mL depending on the 
cell line in order to achieve 40-50% confluency. After 24 hrs, the coverslips were spun 
for 5 min in phosphate buffered saline solution buffer (PBS), thus applying a range of 
forces to the cells proportional to the cell’s radial position in the cover slip. The cells 
were fixed with 4% paraformaldehyde for 15 min, permeabilized in a 00.05% triton 
solution for 40 min, stained with DAPI for 30 min, washed three times with PBS, and 
mounted into slides for imaging. For E0771-GFP+ experiments, the cells were also 
stained against GFP for two hours with a 1:100 dilution of the primary antibody (Abcam 
#ab290) and for one hour with a 1:200 dilution of an anti-rabbit 488 secondary antibody 
with three washes (1% bovine serum albumin [BSA]) after incubation with each antibody 
all at 37C. The number of cells at defined radial positions was quantified by use of a 
fluorescence microscope with a mechanical stage. A Matlab program was used to fit the 
data into sigmoidal and calculate the Τ50 (force required to detach 50% of the cells). [31, 
32] 
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3.3.3 Microfluidic Device Fabrication 
PDMS (Sylgard 184, Dow Corning) microfluidic devices were fabricated as reported 
earlier using a negative photoresist (SU-8 2050, 50-μm thickness, MicroChem) and UV 
photolithography [30]. Patterned negative molds were then exposed to vapor-phase 
tridecafluoro-1,1,2,2-tetrahydrooctyl-1-trichlorosilane (United Chemical Technologies) 
in a vacuum desiccator to prevent adhesion of PDMS. A 5-mm-thick layer of degassed 
PDMS mixture (10:1) was cast onto the mold and cured at 110°C for 20 hrs. Cast PDMS 
devices were peeled off and then punctured for inlet-outlet holes and bonded to glass 
coverslips by exposure to oxygen plasma for 15 s and allowed to bond at 110°C for 
30min. 
3.3.4 GFP lentiviral transduction of E0771 cells 
Stably transduced eGFP-E0771 cells were generated by infecting B16 mouse melanoma 
cells with LV-CMV-GFP lentivirus and sorting for GFP+ cells on an Aria sorter. Briefly, 
cells were seeded at 60% confluency in 6-wells and allowed to attach overnight. The 
cultures were then lentivirally infected at several multiplicity of infections (MOIs) 
ranging from 10 to 50. Four days post-infection, the cells were trypsinized and the GFP 
expression levels assessed in a flow cytometer. The MOI that gave the best efficiency of 
infection, MOI=50, was selected for further use. Two rounds of sorting were performed 
in order to achieve a >99% GFP+ population of cells by use of the BD Aria sorting 
machine. 
3.3.5 Tumor generation and digestion 
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eGFP-E0771 cells were injected (20,000 cells in 20 μL of 1:1 Matrigel to saline solution) 
through he inguinal mammary gland into the abdominal mammary gland of female 
C57BL/6 mice to establish tumors. Tumors were excised after 7 days and digested with 
collagenase D (0.375 U/mL) and hyalurodinase (125 U/mL) for 2-3 hrs at 37 °C with 
mechanical agitation every 30 min, 0.25% trypsin-EDTA (5 min, 37 °C), red blood cell 
lysis buffer (5 min, room temperature), and DNAse (10 min, 0.1mg/mL, room temp). The 
mixture of cells was filtered through a 40 μm filter twice, resuspended in the relevant 
volume of media, and used for the adhesion experiments. 
3.3.6 μSHEAR experiments 
Devices were first washed with ethanol, washed with PBS, either coated with fibronectin 
(10 μg/mL in PBS, 45 min)  and blocked with bovine serum albumin (1% BSA in PBS, 
45 min) or coated with Corning Matrigel™ hESC-Qualified Matrix according to the 
manufacturers guidelines (90 min), and washed with complete media. Cells were then 
introduced at a concentration of 4-10 x10^6 cells/mL and cultured at 37 °C, 5% CO2 
overnight. For digested tumor isolates, a gravity driven media wash was performed 2.5hrs 
post-seeding. The following day, cells were labeled with CellTracker™ Red CMTPX 
Dye (ThermoFisher Scientific #C34552) within the devices according to manufacturer’s 
guidelines. CellTracker™ Red Dye diluted in RPMI1640 was introduced into devices by 
gravity driven flow and stained for 30 min, after which a gravity driven media wash was 
performed. Devices were loaded into a Nikon TE300 microscope equipped with a Ludl 
motorized stage, Spot-RT camera, and Image Pro analysis system and the number of 
GFP+ and CellTrackerRED+ cells was quantified along 8 specific locations.  
Predetermined amounts of force were applied to the cells for a 10 min period by flowing 
 33 
PBS at well-defined flow rates controlled by a Harvard syringe pump. The number of 
GFP+ and CellTrackerRED+ cells was quantified in those same 8 locations at 
predetermined timepoints. 
3.3.7  Statistics  
Data points were plotted using Prism (GraphPad) with a horizontal line representing the 
mean and vertical error bars indicating the standard deviation. Statistical significance 
(p<0.05) was determined using either one way ANOVA with Tukey post hoc test or two 
way ANOVA with Tukey post hoc test as noted with Prism (GraphPad). Sigmoidal non-
linear regression was also used in some parts of the analysis (GraphPad). 
3.4 Results 
3.4.1 Breast cancer cell lines have diverse adhesion properties 
The adhesion signature force of a panel of breast cancer cell lines was measured 
using the spinning disk technology, which applies a linear range of forces to cell attached 
to a fibronectin-coated glass coverslip. Shear flow-mediated detachment of the cells can 
then be quantified at specific radial locations and fitted into a curve to acquire the 50, the 
shear stress at which 50% of the cells detach. Genetic and cell line information on each of 
the cell lines is provided in Table 3, which is adapted from Dai A et al [33]. MCF7-TS 
and MCF7-TR5 are cell lines derived from the MCF7 cell line, which are tamoxifen 
sensitive and resistant, respectively. Representative detachment profiles and curve fits for 
the non-cancerous mammary immortalized hTERT-HME1 cell line and the MDA-MB-
231 and MDA-MD-453 breast cancer cell lines are shown (Figure 2A). After fitting the 
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data into sigmoidal curves, the 50 was calculated (Figure 2B). Non-cancerous 
immortalized mammary cells (hTERT-HME1) had a significantly higher adhesion 
strength signature than all cancerous cell lines (p<0.0001). Furthermore, adhesive 
strength values were significantly different among the majority of the breast cancer cell 
lines tested, suggesting a large degree of variation in adhesive properties among them. 
Table 3. Characteristics of breast cancer cell lines tested. 
Cell line ER PR HER2 
BRCA1 
Mutation 
Subtype Tumor type 








MCF7 + + - WT Luminal A 
invasive ductal 
carcinoma 
ZR751 + +/- - WT Luminal A 
invasive ductal 
carcinoma 










The detachment profile of MDA-MB-231 breast cancer cells was also assessed by 
use of the μSHEAR technology, a microfluidic device that applies varying degrees of 
shear force to adherent cells proportional to the fluid flow through the channel. It is 
important to note that this approach allows for the live monitoring of the detachment of 
the cells, something that is not possible with the spinning disk technology. Figure 2C 
show the sigmoidal fit detachment profiles for the MDA-MB-231 breast cancer cell line. 
While >80% of the cells detach with 200 dynes/cm
2
 of shear force, some remain attached 
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in spite of much higher forces, suggesting the existence of a subpopulation of strongly 
adherent cells within the cell lines. 
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Figure 2 The adhesive strength value of breast cancer cells varies significantly not 
only among cell lines, but also within them. (A) Representative spinning disk 
detachment curves for non-cancerous immortalized mammary cell line hTERT-HME1 as 
well as breast cancer cell lines MDA-MB-231 and MDA-MD-453. The Τ50 is indicated 
with dashed black lines for each cell line. (B) Spinning disk adhesive force measurements 
of a panel of breast cancer cell lines and the hTERT-HME1 immortalized mammary cell 
line. Statistical analysis was performed using one way ANOVA. A non-cancerous 
hTERT-HME1 cells were significantly more adhesive to fibronectin than all the breast 
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Table 4 Tukey's multiple comparisons test results for Figure 2B 
Tukey's multiple comparisons test Significant? Summary 
MDA-MB-453 vs. MDA-MB-231 Yes * 
MDA-MB-453 vs. MCF7 No ns 
MDA-MB-453 vs. MCF7-TS Yes **** 
MDA-MB-453 vs. MCF7-TR5 Yes **** 
MDA-MB-453 vs. ZR-1-75 Yes **** 
MDA-MB-453 vs. MDA-MB-468 Yes **** 
MDA-MB-453 vs. HCC1937 Yes **** 
MDA-MB-453 vs. hTERT-HME1 Yes **** 
MDA-MB-231 vs. MCF7 No ns 
MDA-MB-231 vs. MCF7-TS No ns 
MDA-MB-231 vs. MCF7-TR5 Yes **** 
MDA-MB-231 vs. ZR-1-75 Yes ** 
MDA-MB-231 vs. MDA-MB-468 Yes **** 
MDA-MB-231 vs. HCC1937 Yes **** 
MDA-MB-231 vs. hTERT-HME1 Yes **** 
MCF7 vs. MCF7-TS Yes ** 
MCF7 vs. MCF7-TR5 Yes **** 
MCF7 vs. ZR-1-75 Yes **** 
MCF7 vs. MDA-MB-468 Yes **** 
MCF7 vs. HCC1937 Yes **** 
MCF7 vs. hTERT-HME1 Yes **** 
MCF7-TS vs. MCF7-TR5 Yes ** 
MCF7-TS vs. ZR-1-75 No ns 
MCF7-TS vs. MDA-MB-468 Yes **** 
MCF7-TS vs. HCC1937 Yes **** 
MCF7-TS vs. hTERT-HME1 Yes **** 
MCF7-TR5 vs. ZR-1-75 No ns 
MCF7-TR5 vs. MDA-MB-468 Yes **** 
MCF7-TR5 vs. HCC1937 No ns 
MCF7-TR5 vs. hTERT-HME1 Yes **** 
ZR-1-75 vs. MDA-MB-468 Yes **** 
ZR-1-75 vs. HCC1937 Yes *** 
ZR-1-75 vs. hTERT-HME1 Yes **** 
MDA-MB-468 vs. HCC1937 Yes **** 
MDA-MB-468 vs. hTERT-HME1 Yes **** 
HCC1937 vs. hTERT-HME1 Yes **** 
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3.4.2 Cancer cells adhere less strongly than noncancerous cells 
Given that the immune system plays an important role in tumor formation and 
microenvironment [34, 35], we wanted to use immunocompetent mice to study the 
formation of tumors . Murine C57BL/6-derived E0771 breast cancer cells were used. 
E0771 murine breast cancer cells were infected with a GFP+ lentivirus and selected for 
GFP expression. The genetic modification for GFP expression was done to facilitate the 
isolation of the E0771 cancerous cells from other non-cancerous host cells post-
explantation. E0771-GFP+ cells were then implanted in the mammary fat pad of female 
C57BL/6 mice and allowed to form tumors. After 7 days, tumors were then explanted, 
digested, and sorted into GFP+ E0771 and GFP- host cells. Two cell doses were tested 
for tumor formation (10k and 20k) and their adhesion properties post-explantation were 
analyzed (Figure 3). The E0771-GFP+ mouse cancer cells adhered significantly less 
strongly than their GFP- counterparts (p<0.01), which is consistent with the results 
acquired when measuring the adhesive properties of human breast cancerous and non-
cancerous cell lines (Figure 2B). The cell dose of 20k resulted in a significant difference 
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Figure 3 Differences in adhesive forces between mouse breast cancer cells and non-
cancerous mouse cells are significant. Adhesive properties of GFP+ E0771 and GFP- 
host cells for two doses of E0771 post tumor formation. Statistical analysis was performed 
using a two way ANOVA. Differences were detected for both tumor implantation cell dose 
(p<0.05) and cell type (p<0.01). For the 20k cell dose, a significant difference was detected 
between the GFP+ and GFP- cell fractions (p<0.05; lines denote mean and standard error of the 
mean). 
3.4.3 Culture of cancer cells with non-transformed host cells alters their adhesive 
properties 
Cancer cell lines are often cultured by themselves, which does not recapitulate the 
conditions in which these cells grow in vivo. We were therefore interested in what effects 
co-culture of cancerous cells with non-cancerous host cells would have on the adhesion 
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properties of the cancer cells. In order to assess any changes that occurred to the E0771 
cells during tumor formation, the adhesion properties of E0771 cells before and after 
tumor implantation into C57BL/6 mice were assessed (Figure 4). There is a significant 
(p<0.0001) increase in adhesion strength after tumor formation in a mouse for 7 days. 
Once the GFP+ E0771 breast cancer cells were sorted from the C57BL/6 host cells, a 
significant decrease in adhesion is detected (p<0.0001) suggesting that continued co-
culture with the host cells is required to retain the changes in adhesive properties acquired 
during tumor formation in host mice. Nevertheless, sorted tumor explanted E0771 cells 
continue to have increased adhesion as compared to E0771 in standard culture conditions 
even 24 hrs after sorting (p<0.001), suggesting that the increased adhesiveness of the 
cells persists for some time after withdrawal of the host cells. E0771 cells were also co-
cultured for 24 hrs with C57BL/6 host cells of mice that had not been implanted with 
tumors. An increase in adhesion strength (p<0.001) was observed, although not as 
pronounced as the one detected when the cells were implanted into mice and allowed to 
form tumors. The data suggests that simple co-culture with host cells changes the 
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Figure 4 Implantation into mice or co-culture with mouse host cells causes an 
increase in the adhesion strength of E0771. Spinning disk measured adhesive 
properties of E0771 in standard in vitro culture (black data) and after implantation into 
C57BL/6 mice and tumor formation. Post tumor formation adhesive properties were 
assessed either in co-culture with host cells (blue data) or post-sorting with an Aria cell 
sorter (red data). The same measurements were performed on E0771 cells that had never 
been implanted into mice, but were co-cultured with C57BL/6 isolated cells (orange 
data). Data was analyzed using a one way ANOVA, which detected differences among 
all groups except between the 20k tumor explant sorted and the in vitro co-cult with host 
cells groups (* -significant difference when compared to standard in vitro culture, # - 
significant difference when compared to 20k explant sorted, $ - significant difference 
when compared to 20k explant unsorted, & - significant difference when compared to in 
vitro co-cult with host cells. *,#,$,& p<0.05;  **,##,$$,&& p<0.01;  ***,###,$$$,&&& 
p<0.001; ****,####,$$$$,&&&& p<0.0001). 
 Moreover, we were interested in whether some of the changes in adhesion seen in 
the mouse cancer cells upon co-culture with non-cancerous cells would also be seen in 
human cancer cells. In order to explore this, the effects of co-culture of human 
mesenchymal stem cells (hMSCs) on the adhesive properties of human breast cancer 
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MCF7 cells were studied by means of both the spinning disk and μSHEAR technologies. 
The adhesion strength of MCF7 cells was measured in the spinning disk assay for 
fibronectin (FN)-coated coverslips for three conditions: MCF7 cells cultured in fresh 
media, MCF7 cells cultured in 24hr hMSCs-conditioned media, and MCF7 cells co-
cultured with hMSCs for 24hrs. Although no significant differences in adhesion were 
seen between MCF7 cells cultured in fresh media and conditioned media, a significant 
increase (p<0.0001) of ~36% in adhesion strength was observed when the MCF7 cells 
were cultured with hMSCs (Figure 5A). Similar increases in the adhesion strength of 
MCF7 cells was observed when using the μSHEAR technology in both Matrigel (MT)- 
and FN- coated microfluidic devices (Figure 5B, C). The 50 for each condition was 
calculated. For FN coated surfaces, the 50 of standard cultured MCF7 was 60.3 ± 4.2 
dynes/cm
2
, while 167.4 ± 13.3 dynes/cm
2
for co-cultured MCF7 and 391.5 ± 24.2 
dynes/cm
2
for hMSCs. For MT coated surfaces, the 50 of standard cultured MCF7 was 
67.4 ± 26.0 dynes/cm
2
 and 440.7 ± 24.1 dynes/cm
2 
for co-cultured MCF7. For MT-coated 
surfaces, detachment of hMSCs was minimal even at the highest shear stresses tested and 
it was therefore impossible to calculate a 50. The force required to detach 50% of MCF7 
cells when co-cultured with hMSCs increased threefold and sevenfold as compared to 
MCF7 cells in standard ulture for FN- and MT-coated surfaces respectively, matrices 
chosen because of their abundance in the tumor microenvironment. Taken together, this 
data indicate that stromal cells, either hMSCs in culture or murine tissue cells, have an 




Figure 5 Direct co-culture with hMSCs significantly increases the adhesion strength 
of MCF7 breast cancer cells to both MT and FN coated surfaces. (A) Spinning disk 
measured adhesion strength to FN coated surfaces for MCF7 cells culture in fresh media, 
MCF7 cells culture in hMSC condition media, and MCF7 cells co-cultured with hMSCs. 
(B-C) μSHEAR measured adhesion properties to FN (B) and MT (C) coated microfluidic 
devices of MCF7 human breast cancer cells with cultured by themselves and in co-
culture with hMSCs. Significant (p<0.0001) differences exist in the adhesion properties 
of all groups except for the hMSCs in MT conditions where the data did not converge to 
a sigmoidal curve and was therefore excluded from the analysis. A one way ANOVA was 
performed for the spinning disk data and a sigmoidal linear regression for the μSHEAR 
data.  
3.4.4 μSHEAR-mediated separation of cancerous and non-cancerous cells 
The adhesive properties of the explanted cells were also analyzed using the 
µSHEAR technology. E0771-GFP+ derived tumors were explanted and dissociated, and 
cells were introduced in microfluidic devices coated with either Matrigel (MT) (Figure 6) 
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or fibronectin (FN) (Figure 7). After overnight culture within the devices, the cells were 
stained with CellTrackerRed and exposed to varying amounts of shear stress. Each 
microfluidic device was mounted into a mechanical stage where seven fields of cells 
were identified and a single shear stress was applied for 10 min. At predetermined time 
points, the number of GFP+ and CerllTrackerRed+ cells were quantified at the seven 
predetermined fields of view. The detachment of the two populations of cells, 
GFP+/CellTrackerRed+ E0771 breast cancer murine cells (Figure 6A for MT and Figure 
7A for FN) and GFP-/CellTrackerRed+ host cells (Figure 6B for MT and Figure 7B for 
FN), was assessed using fluorescence microscope and motorized stage, which enabled the 
quantification of cell detachment at specific locations within the devices over time. The 
average detachment for each cell population over time is plotted in Figure 6A-B for MT 
coated surfaces and Figure 7A-B for FN coated surfaces. The collected data allows for 
the calculation of the depletion of GFP+ cells within the devices (Figure 6C for MT and 
Figure 7C for FN) as well as the enrichment of GFP+ outside the devices (Figure 6D for 
MT and Figure 7D for FN). There is a tradeoff between yield (the number of GFP+ cells 
that detach over the original number of GFP+ cells) and purity (the frequency of GFP+ 
cells in the detached fraction of cells), where MT-coated plates enabled a higher yield of 
GFP+ cancer cells to be detached, but at a lower purity. In this condition, around 65% of 
the GFP+ cells were detached at the higher shear stress conditions, but less than a two-
fold enrichment of these cells was achieved. On the other hand, FN-coated devices allow 
for lower yields of detached cancer cells at higher purities. In this condition, only around 
half of the GFP+ cells were detached from the devices, but more than three-fold increases 
in GFP+ E0771 purity was achieved. 
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Figure 6 μSHEAR mediated enrichment and depletion of E0771-CFP+ cells from 
tumor explants in MT coated surfaces. Digested E0771 tumors and surrounding cells 
were introduced into uSHEAR devices coated with Matrigel and exposed to varying 
degrees of shear forces. Detachment of E0771 GFP+ cells (A) and GFP- host cells (B) 
was quantified by use of fluorescence microscopy. Depletion (C) and enrichment (D) of 
GFP+ cells within MT coated uSHEAR devices.  
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Figure 7 μSHEAR mediated enrichment and depletion of E0771-CFP+ cells from 
tumor explants in FN coated surfaces. Digested E0771 tumors and surrounding cells 
were introduced into uSHEAR devices coated with fibronectin and exposed to varying 
degrees of shear forces. Detachment of E0771 GFP+ cells (A) and GFP- host cells (B) 
was quantified by use of fluorescence microscopy. Depletion (C) and enrichment (D) of 
GFP+ cells within FN coated uSHEAR devices.  
 We next tested the ability of the μSHEAR technology to separate human breast 
cancer cells (MDA-MB-231) from non-cancerous immortalized hTERT-HME1. A 
mixture of these cells was inserted into the microfluidic devices and a predetermined 
shear stress was applied. We found that it was possible to enrich for the hTERT-HME1 
inside the device and to consistently detach 90-99% of cancerous MDA-MB-231 (Figure 
8). 
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Figure 8 The μSHEAR technology can separate cancerous from non-cancerous cell 
lines based on adhesion. Fluorescently labeled hTERT-HME1 and MDA-MB-231 were 
introduced into microfluidic devices and exposed to 437dynes/cm
2
 of shear stress. After 
10min, MDA-MB-231 constituted less than 10% of the cell population remaining in the 
device, down from 40-80% in the initial mixture of cells, achieving more than a tenfold 
reduction in cancer cells within the mixture of cells. A two way ANOVA was performed 
(T=1 min p<0.05, T= 5,10 min p<0.0001).  
 
3.5 Discussion 
We have assessed the adhesion properties of a panel of breast cancer lines. There 
were large variations among cell lines in how strongly these cells adhered to FN, which is 
not surprising since many of these cells were derived from different patients, types of 
breast tumors, and by different research groups. Furthermore, other groups have shown 
that there are large variations in integrin expression and their capacity to form focal 
adhesions among breast cancer lines [36], factors that are directly related to the strength 
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variation in adhesion properties highlights the variability in behavior between different 
cancerous tissues and provides further support for a more mechanistic approach to cancer 
therapies and research where organ of origin takes a backseat to the specific genetic 
changes that drove cancer progression. Other studies have also shed light on the 
importance of taking this new approach to cancer classification and treatment [9].  
Immortalized cancer cell lines continue to be used as preclinical models to study 
cancer progression and test potential therapies in spite of numerous studies suggesting 
that they have limited clinical relevance and provide a poor representation of in-patient 
tumor development [20, 21, 37]. Moreover, a wide range of studies have shown that 
cancer cells undergo changes in proliferation and protein expression [38-42]. Here we 
show that implantation of mouse breast cancer cells into mice, as well as at least 24hrs in 
vitro co-culture with mouse primary cells, significantly increases their adhesion. 
Moreover, these changes persisted for at least 24 hrs after removal of the mice primary 
cells supporting published evidence that there is crosstalk between the two cell groups 
and suggesting that these effects are prolonged.  
We corroborated these results by co-culturing human breast cancer cells with 
hMSCs and assessing their adhesion properties. After co-culture with healthy hMSCs, 
cancer cells adhered more strongly to FN and MT, displaying a change in adhesion 
properties reminiscent of those seen in the experiments with mouse cells. Co-culture with 
hMSCs was done because of the crucial role these cells play in cancer progression[43, 
44], however, moving forward it would be interesting to assess whether similar behavios 
are observed with other non-cancerous cells such as breast fibroblasts or cancer 
associated fibroblasts These findings provide additional insights into the crosstalk of 
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cancer cells and other relevant cell types in the tumor microenvironment and highlight 
the need for more complex culture systems than the standard 2D culture widely used 
today.  
Furthermore, our results show that for both mouse and human breast cancer, 
cancerous cell lines adhere less strongly to fibronectin than non-cancerous cell lines and 
healthy primary cells. Although this has been known for other tumors since the 1940s 
[45], our results suggest that isolating cancer cells based on their adhesion properties 
could be possible.  
We pursued this goal and enriched both human and mouse breast cancer cells from 
co-cultures with either non-cancerous mammary cell lines or primary healthy cells. Our 
approach was highly reproducible and, depending on the conditions, achieved a 10-fold 
depletion of cancer cells from the co-cultures for a 3-fold enrichment. The ease of use, 
short time requirement, and reproducibility of our approach makes it a valuable tool for 
enriching cancer cell populations when developing new cancer specific cell lines for 
cancer progression studies and drug testing/validation. Furthermore, the microfluidic 
setup allows for new compartments to be added in the future, which would enable more 
complex co-cultures that recapitulate the in vivo tumor environment more accurately. A 
platform such as this would also allow scientist to test drugs in a well-controlled manner 
and to identify potential biomarkers that correlate with patient treatment responsiveness, 
a major requirement for the progress of personalized cancer treatments to continue to 
advance. 
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In this aim, we have developed a microfluidic technique for the enrichment and 
separation of cancer cells from cell mixtures containing non-cancerous cells. We have 
also shown that large variations exist in the adhesion properties of breast cancer cell line, 
but that these all adhere less strongly than healthy non-cancerous cells. Our results 
highlight the deficiencies of cell lines, particularly when studied in isolation, as non-
cancerous cells are required to recapitulate the in vivo conditions and behaviors of 
cancerous cells. The procedures developed in this aim can also be applied in a modular 
fashion to current cancer organ on a chip systems to allow for the rapid and repeatable 
collection and isolation of cancer cells from these systems.  
Nevertheless, the system can certainly be improved. Enrichment rates achieved are 
around 65%. Improving these should be a priority, perhaps by micro-patterning the 
surface that the cells adhere to. Other, non ECM, ligands could also be used for 
separation. Changes in cadherin expression have been observed in some forms of cancer 
[46, 47]; perhaps enrichment based on cadherin mediated adhesion would yield better 
results than integrin mediated adhesion. Moreover, the method was only tested in one cell 
type in these studies. Validating the technology in other cell lines, human ones in 
particular, should certainly be the next step. Finally, further characterization of the cell 
populations used would be useful. Although we are certain that the GFP- mouse cells 
isolated for the cancer isolation experiments are non-cancerous and can hypothesize that 
they are mostly fibroblasts and adipose cells, determining the exact composition of tis 
population would shed more light on the purification process. 
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CHAPTER 4. µSHEAR MEDIATED PURIFICATION OF TIC 
SUB-POPULATIONS FROM CANCER CELL LINES BASED ON 
ADHESIVE FORCE SIGNATURES 
4.1 Abstract 
Tumor initiating cells (TICs), a subpopulation of cancerous cells within tumors 
responsible for their maintenance, present a major hurdle to cancer treatment and 
recovery because of their resistance to conventional therapies. However, because of their 
low frequency and lack of good markers, TIC purification has proven challenging, even 
in in vitro settings. The interaction between cells and their extracellular environment is of 
critical importance to normal development and function. Integrin receptors mediate this 
interaction by mechanically coupling to an ECM ligand. Many adhesion proteins, 
including integrins, or pathways activated by these proteins have been shown to promote 
TIC stemness. We found that there were significant differences in adhesion strength 
between ALDH
HI
 TIC-like cells and ALDH
LO
 non-TIC cancer cell populations. 
Furthermore, we developed a method for the isolation of TIC populations based on their 
detachment forces which allowed for the enrichment of E0771 cells that formed larger 
(4X volume) tumors faster and higher frequency when implanted into the mammary 




Tumor initiating cells (TICs), a subpopulation of cancerous cells within tumors 
responsible for their maintenance, present a major hurdle to cancer treatment and 
recovery because of their resistance to conventional therapies [48-51]. This resistance 
frequently leads to drug resistant cancer relapse and metastasis development [84-86]. It is 
for this reason that targeting TICs in cancer therapy has attracted such excitement from 
the field [55, 87, 88, 242]. However, because of their low frequency and the lack of good 
markers, TIC purification has proven challenging, even in in vitro settings. 
Many different methods of TIC purification have been developed to exploit 
unique attributes in these cells. Common methods of enrichment include surface marker-
based purification and isolation based on TIC intrinsic functional markers, such as ALDH 
expression, reactive oxygen species (ROS) levels, flow cytometric side population (SP) 
analysis, and mitochondrial membrane potential differences. Many of these purification 
platforms rely on probes such as antibodies and separation technologies such as flow 
cytometry and magnetic beads. Although popular, these methods have several drawbacks 
including high price, non-specificity, inability to scale-up, and lack of robustness, which 
have led to the recent development of biophysical methods of TIC purification based on 
differences in adhesion, stiffness, and niche/scaffold affinity. 
The interaction between cells and their extracellular environment is of critical 
importance to normal development and function [172, 173]. Integrin receptors mediate 
this interaction by mechanically coupling to an ECM ligand, associating with the actin 
cytoskeleton and clustering together [174]. These interactions may strengthen to give rise 
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to focal adhesions, which function as structural links between the cell’s cytoskeleton and 
the surrounding ECM [175]. Abnormal integrin function can lead to a variety of diseases, 
including cancer [176]. Other proteins involved in cell adhesion and focal adhesion 
complex formation such as focal adhesion kinase (FAK) [177, 178] are also dysregulated 
in cancer cells and, along with integrins, contribute to disease progression and metastasis. 
Integrins in particular are often upregulated in many types of cancer and the levels of 
several integrin subtypes are prognostic of disease severity [176]. In addition to having 
important roles in cancer cell survival, migration, and invasion, integrins have been 
shown to cooperate with oncogenes to increase tumorigenesis [176].  
 Cell adhesion proteins are also important for normal development and 
embryogenesis [180]. Integrins are essential for stem cell homing to their niche during 
embryogenesis and development [181]. Several studies have shown the feasibility of 
separating stem cells based on their adhesion levels and integrin expression profiles [30, 
182, 183].   
 Given the vital role that adhesion proteins play in normal stem cell function, it is 
expected that they also play important roles in TICs. In fact, many adhesion proteins or 
pathways activated by these proteins have been shown to promote TIC stemness [189, 
243-245]. FAK ablation results in a depletion of the TIC population [184], integrin αvβ3 
regulates expression of TIC marker CD44 [185] and is necessary to drive stemness and 
EGFR inhibitor resistance for epithelial cancers [186], and integrin α6β1 knockdown 
results in loss of stemness in TICs [187, 188]. In addition to simply being overexpressed 
in TICs, adhesion proteins potentiate TIC function and enable tumor propagation and 
drug resistance [189].  
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 Abnormal expression and function of the cell-ECM adhesion apparatus in TICs 
have allowed groups to isolate them based on their adhesion dynamics. Bansal et al 
isolated prostate TICs from other cancer cells by allowing them to bind to collagen-
coated surfaces for a short period of time. They found that TICs bound faster, and by 
washing away other cells, cancer cells with stem-like properties could be enriched [78]. 
Zhang et al applied the same idea in a more controlled manner to isolate breast cancer 
TICs. They used a microfluidic platform to slowly flow cells through a channel coated 
with selected ECM proteins. Since the TICs interact more rapidly with the ECM, they 
became trapped in the channel, while other cells flowed through [79]. 
It is important to note that adhesion strength separation can be done by exploiting 
differences in the rates at which cells bind to the substrate or differences in the amount of 
force required to detach adherent cells. When exploiting differences in binding rate, the 
cells are slowly rolled over a coated surface and some will bind faster that others 
allowing for separation. On the other hand, when exploiting differences in detachment 
force, cells are allowed to reach some level of adhesion strength with the ECM and then 
forces are applied to separate them. Although this might not seem like a major difference, 
the two assays measure different cell properties which may vary independently: the first 
how fast cells can form adhesion complexes and the second how strongly these adhesion 
complexes bind to the ECM [54].  
Thus far, only differences in binding rate have been exploited to isolate TICs. 
Here, we aim to develop a method for separation of TIC populations based on their 
detachment forces, which might prove more useful, that currently available methods 
since it is generally more scalable and robust. In this study, we measured the adhesion 
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differences between cancer cells expressing TIC markers and non-TIC cancer cells. 
Furthermore, we used the same μSHEAR technology as aim 1 to purify populations of 
cells with higher tumor formation capabilities and validate this by implantation into mice. 
4.3 Materials and methods  
4.3.1 Cell culture 
E0771 cells were cultured in RPMI 1640 supplemented with 10% FBS and 1% penicillin, 
and 1% streptomycin at 37 ºC, 5% CO2 and sub-cultured at 70-80% confluency. The 
xenograft cell line CA2 established from primary human colonic biopsies was cultured in 
suspension in ultra-low-attachment 6-well plate at a density of 100,000 to 150,000 cells 
per well (Corning) as previously described [246]. Briefly, CA2 cells were suspended in a 
serum-free medium containing DMEM/F12 (Life Technologies), 6 mg/mL glucose 
(Sigma), 10 nmol/L progesterone (Sigma), glutamine (Life Technologies), 10 μg/mL 
insulin (Sigma), 13 μg/mL transferrin (Sigma), 15 nmol/L sodium selenite (Sigma), 4 
mg/mL bovine serum albumin (BSA; Sigma), 50 μmol/L putrescine (Sigma), and 15 
mmol/L HEPES (Life Technologies). Cells were supplemented with 10 ng/mL fibroblast 
growth factor and 20 ng/mL epidermal growth factor (Sigma) every other day. Cells were 
sub-cultured every 4-6 days. For adhesion studies, single CA2 cells were plated in tissue 
culture treated 6 wells coated either with fibronectin (10 μg/mL in PBS, 30 min)  and 
blocked with bovine serum albumin (1% BSA in PBS, 30 min) or coated with Corning™ 
Matrigel™ hESC-Qualified Matrix according to the manufacturers guidelines (60 min) 
and cultured for 4 days.  
4.3.2 Spinning disk assay 
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Circular cover slips (25 mm diameter) were washed with ethanol, coated with fibronectin 
(10 μg/mL) for 30 min, and blocked with a 1% solution of bovine serum albumin (BSA) 
for 30 min. Cells were seeded onto fibronectin-coated circular coverslips and cultured 
overnight at concentrations of 100,000-200,000 cells/mL in order to achieve 30-40% 
confluency. After 24 hrs, the coverslips were mounted on the spinning disk device and 
spun for 5 min in phosphate buffered saline solution buffer (PBS), thus applying a range 
of forces to the cells proportional to the cell’s radial position in the cover slip. The cells 
were fixed with 4% paraformaldehyde for 15 min, permeabilized in a 0.05% Triton-X 
solution for 40 min, stained with DAPI for 30 min, washed three times with PBS, and 
mounted into slides for imaging. The number of cells at defined radial positions was 
quantified by use of a fluorescence microscope with a mechanical stage. A Matlab 
program was used to fit the data into sigmoidal and calculate the Τ50 (force required to 
detach 50% of the cells). [31, 32] 
4.3.3 ALDH staining and sorting of CA2 cells  
CA2 cells were trypsinized and stained for ALDH activity using the ALDEFLUOR assay 
(StemCell Technologies) according to the manufacturer’s guidelines. Propidium Iodine 
was used as a dead stain (ThermoFisher) at a 1:1000 dilution. Cells were sorted using a 
BD Aria Cell Sorter. 
4.3.4 Microfluidic device fabrication 
PDMS (Sylgard 184, Dow Corning) microfluidic devices were fabricated as reported 
earlier using a negative photoresist (SU-8 2050, 50-μm thickness, MicroChem) and UV 
photolithography [30]. Patterned negative molds were then exposed to vapor-phase 
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tridecafluoro-1,1,2,2-tetrahydrooctyl-1-trichlorosilane (United Chemical Technologies) 
in a vacuum desiccator to prevent adhesion of PDMS. A 5-mm-thick layer of degassed 
PDMS mixture (10:1) was cast onto the mold and cured at 110°C for 20 hrs. Cast PDMS 
devices were peeled off and then punctured for inlet-outlet holes and bonded to glass 
coverslips by exposure to oxygen plasma for 15 s and allowed to bond at 110°C for 30 
min. 
4.3.5 GFP lentiviral transduction of E0771 cells 
Stably transduced eGFP-E0771 cells were generated by infecting B16 mouse melanoma 
cells with LV-CMV-GFP lentivirus and sorting for GFP+ cells on an Aria sorter. Briefly, 
cells were seeded at 60% confluency in 6-well plates and allowed to attach overnight. 
The cultures were then infected with lentivirus at several multiplicity of infections 
(MOIs) ranging from 10 to 50. Four days post-infection, the cells were trypsinized and 
the GFP expression levels assessed in a flow cytometer. The MOI that gave the best 
efficiency of infection, MOI=50, was selected for further use. Two rounds of sorting were 
performed in order to achieve a >99% GFP+ population of cells by use of the BD Aria 
sorting machine. 
4.3.6 Tumor generation and size measurement 
eGFP-E0771 cells were injected (125-10,000 cells/injection for tumor titration assays and 
250 cells/ injection in tumor growth assays in 20 μL of 1:1 Matrigel to saline solution) 
through he inguinal mammary gland into the abdominal mammary gland of female 
C57BL/6 mice to establish tumors. Tumors diameter sizes were measured in three 
directions at days 9,11,13,15, and 17 using digital calipers. 
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4.3.7 μSHEAR experiments 
Devices were first sterilized with ethanol, washed with PBS, coated with 
fibronectin (10 μg/mL in PBS, 45 min) and blocked with bovine serum albumin (1% 
BSA in PBS, 45 min), and washed with complete media. Cells were then introduced at a 
concentration of 4 x10^6 cells/mL and cultured at 37 °C, 5% CO2 overnight.  
Predetermined amounts of force were applied to the cells for a 10 min period by flowing 
PBS at well-defined flow rates controlled by a Harvard syringe pump. Detached cells 
were collected and attached cells were trypsinized and collected as well. Cells were 
centrifuged, re-suspended in saline solution, counted, and 250 cells/dose were injected 
into C57BL/6 mice. 
4.3.8  Statistics  
Data points were plotted using Prism (GraphPad) with a horizontal line representing the 
mean and vertical error bars indicating the standard deviation or standard error of the 
mean as indicated. Statistical significance (p<0.05) was determined using either one way 
ANOVA with Tukey post hoc test or two way ANOVA with Tukey post hoc test as noted 
with Prism (GraphPad).  
4.4 Results 
4.4.1 Higher levels of TIC marker ALDH activity are correlated with changed adhesion 
strength to ECM coated surfaces 
In order to assess whether TIC phenotype was associated with changed adhesion 
binding strength to ECM protein coated surfaces, a xenograft line established from 
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primary human colonic biopsies, CA2, with a large population of cells having high 
activity for TIC marker ALDH was used in conjunction with the spinning disk assay. The 
frequency of CA2 cells with TIC marker ALDH
HI
 activity was determined to be 20-30% 
using the StemCell Technologies ALDEFLUOR assay and a BD Aria Cell Sorter (Figure 
9A,B). These cells were cultured and expanded in suspension culture. It was therefore 
necessary to verify that transition into the adhesion culture required to perform the 
spinning disk assay did not decrease the frequency of ALDH
HI
 TIC cells. CA2 cells were 
cultured in FN and MT coated surfaces for 4 or 7 days and the activity levels of ALDH 
assessed. Although 4 days in adhesive culture did not decrease the ALDH
HI
 TIC fraction 
in either matrix culture condition, culture for additional three days did result in large 
decreases in TIC fraction for both matrices (Figure 9C,D).  
Once it was confirmed that adhesive culture for short periods of time (4 days) did 
not affect the frequency of ALDH
HI
 TICs in CA2 culture, the cells were transferred into 





 subpopulations. The spinning disk analysis was performed on 
50 calculated for each of them (Error! Reference 
source not found.E,F). Interestingly, although ALDH
HI
 cells had higher adhesion 
binding strengths in MT coated surfaces, in FN coated surfaces the opposite was 
observed, suggesting that TICs may bind differentially to ECM proteins. 
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Figure 9. Populations of ALDH
HI
 CA2 TICs have unique adhesion strength 
signatures. CA2 cells were stained for ALDH activity by means of the ALDEFLUOR 
assay (A,B). ALDH activity levels were assessed in adhesion culture conditions and no 
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decrease in activity was seen after 4 days. Quantified data (C) as well as a representative 
staining in the Aria sorter (D) are shown. The spinning disk technology was used to 




 subpopulations in 
MT (E) and FN (F) coated surfaces. A non-parametric Mann-Whitney test was used (** 
p<0.01, *** p<0.001) 
4.4.2  E0771 cells with a specific adhesive signature have higher tumour formation 
capabilities 
To better assess the differences in adhesion strength of TICs vs non-TICs, the 
E0771 mouse breast cell line was chosen, which allowed for immune competent 
C57BL/6 mice to be used for implantation studies. A tumor titration assay was performed 
over a range of E0771-GFP+ cell dose (125-10,000 cells) injections into the mammary 
pad of C57BL/6 female mice and the tumor size were determined by calliper 
measurements of the diameter at predetermined time points (Figure 10A). Generally, as 
cell dose was decreased, the speed at which tumors formed decreased and the size of the 
resulting tumors decreased. However, for doses lower than 250 cells/injection, this trend 
was not as marked. For further experimentation, a dose at that caused a significant lag 
time for tumor formation and formed small to medium sized tumors that could be 
measured for a 5-7 day range would be ideal, which is why an injection dose of 250 
cells/injection was chosen. 
For these assays, FN was chosen as the ECM protein to coat the µSHEAR devices 
because of its crucial role in breast cancer invasiveness and migration [247]. 
Furthermore, mammary epithelial cell interactions with fibronectin have been shown to 
induce EMT [248], which in turn is correlated with TIC properties. 
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After identifying the optimal E0771 injection dose, µSHEAR-based separation of 
the cells was performed. Cells were introduced into the microfluidic devices and each 
device was exposed to one of three predetermined amounts of shear stress; 110 
dynes/cm
2
 (Figure 10B), 220 dynes/cm
2
 (Figure 10C), or 330 dynes/cm
2
 (Figure 10D). 
The cells that detached upon applying the shear stress (detached fraction in Figure 10) 
and the cells that remained attached the device (attached fraction in Figure 10) were 
collected. For some devices, the entire population of cells inside the device was 
trypsinized and collected to serve as controls. The different cell fractions were counted 
and the correct cell dose was injected into the mammary pad of C57BL/6 female mice. 
Tumor sizes were measured at 9, 11, 13, 15, and 17 days post injection by use of 
callipers. Interestingly, the cells detached at 220 dynes/cm
2 
produced significantly larger 
tumors after 15 and 17 days relative to the control group, unsorted E0771 cells. 
Furthermore, the remaining fraction of adherent cells at 220 dynes/cm
2
 yielded 
significantly smaller tumours than both the detached fraction and the control group. For 
cells exposed to 110 dynes/cm
2
, there was a slight, but significant decrease in the tumor 
volumes for the attached fraction as compared to the control group after 15 days post 
injections. No differences were detected for any of the groups exposed to 330 dynes/cm
2
. 
Figure 10E shows the final tumor volumes for both the attached and detached fractions of 
cells for all shear stress conditions. The green line represents the average volume for the 
control group, mice that were injected with unsorted E0771-GFP+ cells. 
In addition to measuring tumor sizes, the lag time for sizeable tumor formation 
was measured (Figure 10F). In addition to the detached fraction of cells exposed to 220 
dynes/cm
2
 forming larger tumors, these cells also formed tumors faster than the unsorted 
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control group and at a higher frequency. The attached fraction exposed to 220 dynes/cm
2
, 
on the other hand, took longer than both the control group and the detached fraction to 
form tumors and did not form as frequently. 
Taken together, these results suggest that most of the TIC population within the 
E0771 cell line require shear stresses that are higher that 110 dynes/cm
2
 and around 220 
dynes/cm
2
 to detach from FN coated surfaces. This unique adhesion strength signature 
allows them to be enriched with shear stresses of 220 dynes/cm
2
. These cells yield tumors 
with more frequency that grow faster and reach larger sizes relative to the cells that 
remain attached to the FN coated surfaces when exposed to this level of shear force as 
well as compared to non-sorted E0771. 
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Figure 10 Adhesion mediated purification of E0771 TICs. A tumor titration was 
performed by injecting different doses of E0771 cells into the mammary fat pad of 





 (C), or 330dynes/cm
2
 (D) of shear stress and sorted based on adhesion 
strength. Unsorted cells from devices not exposed to shear stress were used as controls. 
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female mice using a dose of 250 cells/injection and the growth of the tumors was 
measured. Detached cells exposed to 220dynes/cm
2
 formed significantly larger tumors as 
compared to any of the other cell fractions (E) and they formed them faster and with 
higher frequency (F). Panels B-E were analyzed using two way ANOVAS (Graphs show 
means and standard error of the mean. Symbols denote: $ - significant difference between 
detached fraction and attached fraction, # - significant difference between detached 
fraction and control group, & - significant difference between control group and attached 
fraction. *,#,$,% p<0.05;  **,##,$$,%% p<0.01;  ***,###,$$$,%%% p<0.001; 
****,####,$$$$,%%%% p<0.0001)  
4.5 Discussion 
The discovery of tumor initiating cells and the characterization of the role that they 
play in tumor progression, metastasis, and relapse have revolutionized our approach to 
cancer and its treatment [249-251]. In fact, because of our better understanding of the 
importance of TICs, novel therapeutic agents have been developed and are currently 
being evaluated in clinical and preclinical studies [252]. Most of these novel therapies 
could be used in conjunction with traditional therapies, such as chemotherapy, to target 
both the non-TIC and the TIC subpopulations of cells within tumors [252].  
In order to efficiently develop novel TIC targeting therapies, it is necessary to 
develop robust, straightforward, reproducible, and rapid methods for TIC enrichment that 
will enable their enrichment for research and drug testing purposes as well as, later on,  
for diagnostic purposes when deciding the optimal therapeutic regimes for patients. Here, 
we examined the potential differences in adhesion between the non-TIC and TIC 
populations of cancer cells. Moreover, we developed a microfluidic method to enrich for 
cancer cells with the ability to form more and larger tumors faster, all of which are 
hallmarks of TIC phenotype.  
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In order to study the potential differences in adhesion signatures between non-TIC 
cancer cells and TICs, a xenograft line established from primary human colonic biopsies, 
CA2, with a large population of cells having high activity for ALDH was used. ALDHs 
are a family of enzymes that play a role in the metabolism of aldehydes [154]. Studies 
dating more than a decade have described a correlation between high levels of ALDH and 
stemness and succeeded in isolating hematopoietic stem cells based on ALDH activity 
[155-157]. More recently, high ALDH levels have been associated with other stem cell 
types and with TICs [71, 72, 158-160]. The large percentage of cells with high ALDH 
activity in the CA2 cell line facilitated their isolation by means of a cell sorter and the 
measurements in adhesion strength by use of a spinning disk, which requires relatively 
large numbers of cells. Furthermore, the suspension culture conditions the cells are 
expanded in, its xenographt nature, and the short time since derivation all should make 
this cell line more representative of in vivo cancer cells relative to standard cell lines 
derived decades ago.  





 non-TIC cancer cells in both MT and FN coated surfaces. 
Interestingly, ALDH
HI 
cells bound more strongly in MT coated surfaces and less strongly 
in FN coated surfaces, suggesting that TICs may bind preferentially to some ECM 
proteins. The lowered adherence of the ALDH
HI
 TICs to FN coated surfaces was also 
observed in mouse E0771 cells with tumor formation capabilities. The shared decrease in 
adhesion strength for the TIC-like subpopulations of both E0771 and CA2 cells, from 
mouse mammary and human colonic origins respectively, suggests that perhaps this 
lowered adhesive signature to FN coated surface could be a characteristic of all TICs. 
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Nevertheless, the data presented here is not sufficient to ascertain whether this is a 
commonality across tumor types and more studies with a variety of other cancer cell lines 
will be necessary to reach that conclusion.  




 populations of CA2 cancer cells, we examined whether differences in 
adhesive signatures could be exploited to enrich for TICs by using a functional tumor 
formation assay. To this end, and because the immune system is known to play a key role 
in tumor formation and microenvironment, it was determined that a murine cancer cell 
line that allowed the use of an immunocompetent mouse model for tumor formation 
should be used. Several cell lines were tested and the E0771 cell line was selected 
because of its ability for form tumors in a timely manner and their high survival within 
microfluidic channels.  
We found that it was possible to enrich for cancer cells that formed significantly 
larger tumors, faster, and with a higher frequency of tumor formation by enriching for 
cells that detached from FN coated surfaces when 220 dynes/cm
2
 of shear stress was 
applied. When applying a lower shear stress of 110 dynes/cm
2
, the enrichment for cancer 
cells with these tumor formation was not seen, perhaps because enough enrichment was 
not being achieved to detect a difference between the detached fraction and the control 
unsorted population of E0771 cancer cells. Surprisingly, a significant difference was not 
detected when a higher amount of shear stress of 330 dynes/cm
2 
was applied. This may 
be because the larger shear stresses affect the health of the cell population leading to 
larger amounts of cell death and lower tumor formation capabilities. Although exciting, it 
will be necessary to examine whether we are able to repeat the process with other cancer 
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cell lines, human cancer cell lines, and even primary tumors. It will be necessary to run 
further controls in this assay to determine if the exposure to flow negatively impacts the 
health of the cancer cells. One way to do this is to mix the attached and detached cell 
populations for each shear stress condition and determine the tumor formation 
capabilities of the whole cell population post exposure to shear stress based sorting. 
In this aim, we studied the differences in adhesion strength between TIC and non-
TIC cancer cell populations and exploited these differences in order to develop a 
microfluidic technique for the enrichment and separation of TICS from cancer cell 
populations. Our results serve as a proof of principle for adhesion based TIC enrichment 
which could have powerful applications for studies into the biology of these cells, the 
search for effective therapeutic targets in them, and potentially their detection in 
diagnostic settings for the determination of the optimal therapeutic regime. 
Further work on this aim should focus of the in vitro characterization of the 
enriched TIC-like cells and reproducing the enrichment process with other mouse cancer 
cells as well as human cancer cells. In terms of in vitro characterization, extreme limiting 
dilution assays, surface marker expression profiles, and single cell sequencing could 
further establish the enriched cells as TICs. Moreover, it wold be interesting to look at the 
expression levels of different integrins, and other cell adhesion molecules such as focal 





CHAPTER 5. FUTURE CONSIDERATIONS 
The objective of this thesis was to examine the adhesive properties of cancer cells 
and any differences that might exist both between them and non-tumorigenic cells as well 
as among the different cancer cell subpopulations. We have demonstrated that these 
differences do exist, with cancer cells being less adhesive than their non-transformed 
counterparts and TICs having unique adhesive signatures. Furthermore, we developed a 
microfluidic technology that isolates cancer cells and enriches for TICs based on the 
differences in adhesive properties that were identified 
In Aim 1, we studied the adhesive properties of a panel of breast cancer cells and 
found that there were large degrees of variability among them, in part due to the 
differences in sourcing of these cell lines. Nevertheless, we found that all cancer cell lines 
adhered significantly less strongly to ECM proteins than non-tumorigenic cells. While 
performing the adhesion studies, we found that the adhesive properties of cancer cells, of 
both human and mouse origin, significantly change when allowed to interact with other 
non-transformed host cells, confirming reports in the literature that studying cancer cells 
in isolation does not accurately recapitulate the properties or conditions that these cells 
exhibit and are exposed to in vivo. Moreover, we were able to enrich mouse cancer cells 
from a mixture of tumorigenic and non-transformed host mouse cells derived from 
tumors. 
In Aim 2, we studied the adhesive properties of TIC populations and any 
differences that might exist between them and their non-TIC cancer cell counterparts. We 
found that colonic cancer cells expressing high levels of TIC marker ALDH had 
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significantly different adhesion properties when compared to cells with low ALDH 
activity. Interestingly, ALDH
HI
 cells bound more strongly to MT, but less strongly to FN, 
suggesting that they preferentially bind to certain ECM properties perhaps because of 
different integrin expression profiles in TICs. TICs were also isolated from the E0771 
mouse breast cancer cell lines based on their adhesive properties and these cells were 
capable of forming more and larger tumors faster when implanted into in the mammary 
fatpad of female C57BL/6 mice, key properties of TICs. 
Futures studies should focus on verifying some of the results we have presented 
here in other mouse cell lines, human cell lines, and ultimately primary human tumors. In 
terms of the adhesion based enrichment of cancer cells, the studies presented here were 
done with tumors created by injecting cancer cells into mice mammary pads. It would be 
interesting to see if tumors isolated from a spontaneous tumor generating mouse model 
also display the same adhesion differences between cancerous and non-cancerous cells. 
Ultimately, performing these studies with primary human tumors would make the 
technology much more powerful and applicable in the cancer field. Adding micro 
patterns to the surface of the microfluidic channels could also be tested in order to 
increase the purity of the isolated cells. 
 The modular aspect of the microfluidic technology used here could allow for other 
compartments to be added such that cancer cells could be co-cultured with other cell 
types to better recapitulate in vivo conditions. This would create a full and closed cancer 
cell culture and purification system with powerful uses in future cancer research.  
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Future studies in the TIC enrichment portion of the studies should also focus on 
translating the technology from mouse cells to human cells. Studying whether human 
TICs also display an adhesive signature would certainly be useful given that one of the 
main limitations of the results shown here is that the work was done in mouse cells and 
only with one cell line. It would also be interesting to investigate whether the purified 
TICs have higher metastatic potential in addition to the increased tumor formation 
capabilities observed here.  
Overall, the studies presented in this thesis begin to address the potential of 
adhesion based enrichment of cancer cells and TIC subpopulations. Although more work 
is needed, the ability to enrich TICs specifically without the use of markers and with a 
technology as cheap, easy to use, and fast as the one developed here could provide 
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